TITLE

The Industry

PUB. DATE
October 2008
SOURCE
Pharmaceutical Representative;Oct2008, Vol. 38 Issue 10, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry. Abbot Laboratories Inc. and AstraZeneca PLC have formed a partnership in promoting AstraZeneca's Crestor, a cholesterol medication, in the U.S. Roche Pharmaceuticals has signed an agreement to acquire Mirus Bio Corp. for $125 million. Bayer Schering Pharma AG has agreed to buy the preclinical oncology portfolio of Nycomed Inc. for around $76.5 million in up-front and milestone payments.
ACCESSION #
34773786

 

Related Articles

  • Mims UPDATE.  // GP: General Practitioner;12/16/2002, p37 

    Presents various developments related to pharmaceutical industry in Great Britain as of December 16, 2002. Launch of Tamiflu (oseltamivir) by Roche AG for the treatment and prevention of influenza; Grant of license to AstraZeneca PLC's Arimidex (anastrozole) for use as an adjuvant therapy for...

  • More to Share. Agres, Ted // Drug Discovery & Development;Sep/Oct2013, Vol. 16 Issue 5, p6 

    The article offers information on growing role of pharmaceutical companies in increasing drug discovery and chances of their clinical success. It is noted that Roche Holding AG and AstraZeneca PLC have agreed to share data and test results from selected early-stage small-chemical drug candidates...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;7/15/2002, Vol. 262 Issue 2, p12 

    Cites update on the pharmaceutical industry as of July 15, 2002. Approval received by Astrazeneca in Japan for its cancer drug; Companies which received U.S. Food and Drug Administration approval for a generic version of the spasticity drug Zanaflex; Drugs from Roche and Gilead Sciences Inc....

  • FOCUS ON EUROPEAN NEWS.  // Applied Clinical Trials;Nov2001, Vol. 10 Issue 11, p66 

    Reports developments on pharmaceutical industry in Europe as of November 2001. Approval on the release of Roche's oral cancer drug Xeloda by Food and Drug Administration; Approbation to market the insulin analogue NovoRapid from Novo Nordisk A/S; Permission to release the Casodex from AstraZeneca.

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;May 2004, Vol. 3 Issue 5, p3 

    Reports global developments related to pharmaceutical companies as of May 2004. Financial performance of Roche Pharmaceuticals company in the first quarter of year 2004; Plans of AstraZeneca PLC to launch a new drug; Use of legal proceedings to protect marketing exclusivity for the antifungal...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;May 2004, Vol. 3 Issue 5, p4 

    Reports developments related to cancer drug development as of March 15, 2003. Schedule on the launch of AstraZeneca PLC's Faslodex drug; Total sales of Roche Pharmaceuticals company's MabThera drug in the year 2003; Court order stating that Genentech Inc.'s breast cancer drug Herceptin did not...

  • Investing in New Drugs. Riesenman, Stephanie // Drug Discovery & Development;Dec2003 Supplement, Vol. 6, p8 

    Ranks the top 10 pharmaceutical companies in order of revenue for 2002 and amount of spent on research and development as a function of total revenue for the year. Spate of drug development projects and innovative technologies; Astra Zeneca; Aventis; Pfizer; Wyeth Pharmaceuticals; Roche Group. ...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;7/15/2002, Vol. 262 Issue 2, p12 

    Cites update on the pharmaceutical industry as of July 15, 2002. Approval received by Astrazeneca in Japan for its cancer drug; Companies which received U.S. Food and Drug Administration approval for a generic version of the spasticity drug Zanaflex; Drugs from Roche and Gilead Sciences Inc....

  • New in the marketplace.  // Drugs & Therapy Perspectives;Sep2003, Vol. 19 Issue 9, p26 

    Presents a list that contains a summary of drug product launches and approvals identified in international markets as of September 2003. Emtriva from Gilead Sciences; Fuzeon from Roche; Certican from Novartis; Iressa from AstraZeneca.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics